TY - JOUR
T1 - Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia
AU - Denys, B.
AU - Van Der Sluijs-Gelling, A. J.
AU - Homburg, C.
AU - Van Der Schoot, C. E.
AU - De Haas, V.
AU - Philippé, J.
AU - Pieters, R.
AU - Van Dongen, J. J.M.
AU - Van Der Velden, V. H.J.
N1 - Funding Information:
This study was supported by a grant from the Dutch Cancer Society (grant EMCR 2005-3428) and a grant from the Stichting tegen Kanker (ref 226.2008). We gratefully acknowledge the technicians from the laboratory of the DCOG, the working group Leukemia and Lymphoma Diagnostics (Department of Immunology, Erasmus MC) and Sanquin and all clinicians and patients participating in the DCOG-ALL10 protocol.
PY - 2013/3
Y1 - 2013/3
N2 - Most current treatment protocols for acute lymphoblastic leukemia (ALL) include minimal residual disease (MRD) diagnostics, generally based on PCR analysis of rearranged antigen receptor genes. Although flow cytometry (FCM) can be used for MRD detection as well, discordant FCM and PCR results are obtained in 5-20% of samples. We evaluated whether 6-color FCM, including additional markers and new marker combinations, improved the results. Bone marrow samples were obtained from 363 ALL patients at day 15, 33 and 78 and MRD was analyzed using 6-color (218 patients) or 4-color (145 patients) FCM in parallel to routine PCR-based MRD diagnostics. Compared with 4-color FCM, 6-color FCM significantly improved the concordance with PCR-based MRD data (88% versus 96%); particularly the specificity of the MRD analysis improved. However, PCR remained more sensitive at levels <0.01%. MRD-based risk groups were similar between 6-color FCM and PCR in 68% of patients, most discrepancies being medium risk by PCR and standard risk by FCM. Alternative interpretation of the PCR data, aimed at prevention of false-positive MRD results, changed the risk group to standard risk in half (52%) of these discordant cases. In conclusion, 6-color FCM significantly improves MRD analysis in ALL but remains less sensitive than PCR-based MRD-diagnostics.
AB - Most current treatment protocols for acute lymphoblastic leukemia (ALL) include minimal residual disease (MRD) diagnostics, generally based on PCR analysis of rearranged antigen receptor genes. Although flow cytometry (FCM) can be used for MRD detection as well, discordant FCM and PCR results are obtained in 5-20% of samples. We evaluated whether 6-color FCM, including additional markers and new marker combinations, improved the results. Bone marrow samples were obtained from 363 ALL patients at day 15, 33 and 78 and MRD was analyzed using 6-color (218 patients) or 4-color (145 patients) FCM in parallel to routine PCR-based MRD diagnostics. Compared with 4-color FCM, 6-color FCM significantly improved the concordance with PCR-based MRD data (88% versus 96%); particularly the specificity of the MRD analysis improved. However, PCR remained more sensitive at levels <0.01%. MRD-based risk groups were similar between 6-color FCM and PCR in 68% of patients, most discrepancies being medium risk by PCR and standard risk by FCM. Alternative interpretation of the PCR data, aimed at prevention of false-positive MRD results, changed the risk group to standard risk in half (52%) of these discordant cases. In conclusion, 6-color FCM significantly improves MRD analysis in ALL but remains less sensitive than PCR-based MRD-diagnostics.
KW - acute lymphoblastic leukemia
KW - childhood
KW - flow cytometry
KW - minimal residual disease
KW - real-time quantitative PCR
UR - http://www.scopus.com/inward/record.url?scp=84875223442&partnerID=8YFLogxK
U2 - 10.1038/leu.2012.231
DO - 10.1038/leu.2012.231
M3 - Article
C2 - 22945774
AN - SCOPUS:84875223442
SN - 0887-6924
VL - 27
SP - 635
EP - 641
JO - Leukemia
JF - Leukemia
IS - 3
ER -